Charles River Laboratories International Aktie 1097832 / US1598641074
185.79
USD
3.72
USD
2.04%
20.12.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Charles River Laboratories International Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2022 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2021 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2020 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2019 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2018 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2017 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2016 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2015 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
| 2014 | Charles River Laboratories International Inc. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Charles River Laboratories International
| 9.2 23 | 9.5 22 | 7.6 21 | 7.2 20 | 5.1 19 | 4.6 18 | 2.5 17 |
Umsatz je Aktie- Charles River Laboratories International
| 80.3 23 | 77.5 22 | 68.8 21 | 57.8 20 | 52.7 19 | 46.2 18 | 38.3 17 |
KGV- Charles River Laboratories International
| 25.6 23 | 23.0 22 | 48.6 21 | 35.0 20 | 30.0 19 | 24.2 18 | 43.1 17 |
Charles River Laboratories International Inc.: Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 |
| Gewinn je Aktie unverwässert | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 |
| Gewinn je Aktie verwässert | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Charles River Laboratories International Inc.: Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 80.26 | 77.50 | 68.84 | 57.77 | 52.75 | 46.23 | 38.25 |
| KGV (Jahresendkurs, EPS unverwässert) | 25.63 | 22.99 | 48.56 | 34.97 | 29.96 | 24.19 | 43.09 |
| KGV (Jahresendkurs, EPS verwässert) | 25.63 | 22.99 | 48.56 | 34.97 | 29.96 | 24.19 | 43.09 |
| KGV (Jahresendkurs) | 25.63 | 22.99 | 48.56 | 34.97 | 29.96 | 24.19 | 43.09 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 44.65 | 39.77 | 36.90 | 39.04 | 35.51 | 34.71 | 36.32 |
| Fremdkapitalquote in % | 55.35 | 60.23 | 63.10 | 60.96 | 64.49 | 65.29 | 63.68 |
Charles River Laboratories International Inc.: GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 4’129.41 | 3’976.06 | 3’540.16 | 2’923.93 | 2’621.23 | 2’266.10 | 1’857.60 |
| Umsatzveränderung in % | 3.86 | 12.31 | 21.08 | 11.55 | 15.67 | 21.99 | 10.48 |
| Bruttoergebnis vom Umsatz | 1’391.74 | 1’316.07 | 1’209.65 | 964.02 | 871.31 | 771.05 | 653.97 |
| Bruttoergebnisveränderung in % | 5.75 | 8.80 | 25.48 | 10.64 | 13.00 | 17.90 | 8.42 |
| Operatives Ergebnis | 661.13 | 652.59 | 602.43 | 458.96 | 392.59 | 358.13 | 296.86 |
| Veränderung Operatives Ergebnis in % | 1.31 | 8.33 | 31.26 | 16.90 | 9.62 | 20.64 | 11.56 |
| Ergebnis vor Steuern | 581.28 | 622.99 | 480.71 | 447.11 | 304.08 | 281.68 | 296.96 |
| Veränderung Ergebnis vor Steuern in % | -6.69 | 29.60 | 7.51 | 47.04 | 7.95 | -5.14 | 33.21 |
| Ergebnis nach Steuer | 474.62 | 486.23 | 390.98 | 364.30 | 252.02 | 224.87 | 123.49 |
| Veränderung Ergebnis nach Steuer in % | -2.39 | 24.36 | 7.32 | 44.55 | 12.07 | 82.09 | -20.06 |
Charles River Laboratories International Inc.: Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 4’536 | 4’579 | 4’432 | 3’347 | 3’026 | 2’518 | 1’866 |
| Langzeit Gesamtverbindlichk. pro Aktie | 67.80 | 68.46 | 67.34 | 50.38 | 47.33 | 40.64 | 29.59 |
| Eigenkapital | 3’659 | 3’024 | 2’592 | 2’144 | 1’666 | 1’338 | 1’064 |
| Veränderung Eigenkapital in % | 20.85 | 17.42 | 19.87 | 29.37 | 24.08 | 26.05 | 24.89 |
| Bilanzsumme | 8’195 | 7’603 | 7’024 | 5’491 | 4’693 | 3’856 | 2’930 |
| Veränderung Bilanzsumme in % | 7.79 | 8.24 | 27.93 | 17.01 | 21.70 | 31.60 | 8.04 |
Charles River Laboratories International Inc.: Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -3.18 | 23.09 | 5.74 | 42.16 | 9.54 | 81.59 | -20.97 |
| Gewinn je Aktie (verwässert) | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 |
| Veränderung Gewinn je Aktie (verwässert) in % | -2.67 | 24.66 | 5.63 | 41.93 | 9.82 | 81.82 | -21.36 |
| Anzahl Mitarbeiter | 21’800 | 21’400 | 20’000 | 18’400 | 17’100 | 14’700 | 11’800 |
| Veränderung Anzahl Mitarbeiter in % | 1.87 | 7.00 | 8.70 | 7.60 | 16.33 | 24.58 | 7.27 |
Charles River Laboratories International Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Charles River Laboratories International Inc. | Quartalszahlen | 12.02.2025 |
| Charles River Laboratories International Inc. | Quartalszahlen | 08.05.2025 |
| Charles River Laboratories International Inc. | Quartalszahlen | 30.07.2025 |
| Charles River Laboratories International Inc. | Quartalszahlen | 29.10.2025 |
Charles River Laboratories International Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 06.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 07.08.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 09.05.2024 |
| Hauptversammlung | Annual General Meeting | 08.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 14.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 08.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 09.08.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 11.05.2023 |
| Hauptversammlung | Annual General Meeting | 09.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 22.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 02.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 03.08.2022 |
| Hauptversammlung | Annual General Meeting | 10.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 04.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 16.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98.92 |
| The Vanguard Group, Inc. | 11.69 |
| Vanguard Group, Inc. (Subfiler) | 11.48 |
| Wellington Management Co. LLP | 7.32 |
| Wellington Management Co. LLP (Wellington Breakout) | 6.56 |
| State Street Corp. | 4.17 |
| Kayne Anderson Rudnick Investment Management LLC | 3.79 |
| BlackRock Fund Advisors | 3.46 |
| Allspring Global Investments LLC | 3.42 |
| Vanguard Total Stock Market ETF | 3.19 |
| Allspring Special Mid Cap Value Fund | 2.88 |
| Vanguard 500 Index Fund | 2.68 |
| Vanguard Small Cap Index Fund | 2.53 |
| BlackRock Institutional Trust Co. NA | 2.42 |
| Geode Capital Management LLC | 2.38 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 11’800 | 14’700 | 17’100 | 18’400 | 20’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.16 | 0.15 | 0.15 | 0.16 | 0.18 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 827 | 898 | 1’021 | 1’201 | 1’274 |
| Summe Anlagevermögen | 2’103 | 2’958 | 3’671 | 4’290 | 5’750 |
| Summe Aktiva | 2’930 | 3’856 | 4’693 | 5’491 | 7’024 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1’866 | 2’518 | 3’026 | 3’347 | 4’432 |
| Summe Eigenkapital | 1’064 | 1’338 | 1’666 | 2’144 | 2’592 |
| Summe Passiva | 2’930 | 3’856 | 4’693 | 5’491 | 7’024 |
Adresse
| 251 Ballardvale Street, 01887 Wilmington | |
| Telefon | +1 (781) 222-6000 |
| URL | http://www.criver.com |
Management
|
Barbara J. Patterson
Senior VP-Regulatory Affairs & Compliance |
|
Birgit Girshick
Chief Operating Officer & Executive Vice President |
|
Brian Bathgate
Senior Vice President-European Safety Assessment |
|
Colin Dunn
Senior VP, GM-Research Models & Services |
|
Craig B. Thompson
Independent Director |
|
Deborah Turner Kochevar
Independent Director |
|
Flavia H. Pease
Chief Financial Officer & Executive Vice President |
|
Foster T. Jordan
Senior Vice President-Microbial Solutions |
|
George E. Massaro
Lead Independent Director |
|
George Llado
Independent Director |
|
Gina M. Mullane
Chief Marketing Officer & Senior Vice President |
|
James C. Foster
Chairman, President & Chief Executive Officer |
|
John C. Ho
Chief Strategy Officer & SVP-Corporate Strategy |
|
Joseph W. LaPlume
Executive VP-Corporate Development & Strategy |
|
Julie Frearson
Chief Scientific Officer & Senior Vice President |
|
Kristen M. Eisenhauer
Senior VP-Client Services & Sales Management |
|
Mark Mintz
Chief Information Officer & Senior Vice President |
|
Martin W. MacKay
Director |
|
Matthew L. Daniel
Secretary, Chief Compliance Officer & Senior VP |
|
Michael Gunnar Knell
Chief Accounting Officer & Senior Vice President |
|
Nancy C. Andrews
Independent Director |
|
Reshema Kemps-Polanco
Independent Director |
|
Richard F. Wallman
Independent Director |
|
Robert J. Bertolini
Independent Director |
|
Shannon M. Parisotto
Senior VP-Global Operations & Controller |
|
Todd Spencer
Vice President-Investor Relations |
|
Victoria L. Creamer
Chief People Officer & Executive Vice President |
|
Virginia M. Wilson
Independent Director |
|
William D. Barbo
Chief Commercial Officer & Executive VP |